Martinsried/Munich, April 2, 2008. MediGene AG (Frankfurt, Prime Standard: MDG) announced today that the European Patent Office has granted a patent on the EndoTAG® technology which covers certain cationic liposomal compositions containing cytotoxic agents. The patent portfolio hence protects the substance EndoTAG®-1 developed by MediGene as a drug for the treatment of various types of cancer, and extends the protection to EndoTAG® compositions with various active agents for the combat against cancer as well as other diseases. MediGene recently achieved excellent efficacy data in a phase II trial of the drug candidate EndoTAG®-1 in the indication pancreatic cancer, verifying the mode of action of EndoTAG®.
